New Anticoagulants: Focus on Currently Approved Oral Factor Xa and Factor IIa Inhibitors

Essential Guide to Blood Coagulation

Volumn , Issue , 2010, Pages 91-102

  Malmström, Rickard E ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dabigatran clinical efficacy and safety; Dabigatran etexilate orally bio available dabigatran prodrug; Ecarin clotting time (ECT); New anticoagulants; New anticoagulants and therapeutic monitoring; Pivotal phase III studies dabigatran efficacy and safety; Randomized, double blind, phase III studies RECORD1 and RECORD2; Rivaroxaban (Xarelto , Bayer HealthCare AG) oral low molecular weight direct factor Xa (FXa) inhibitor; Therapeutic drug monitoring (TDM) needs

Indexed keywords

EID: 84886232541     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444314465.ch9     Document Type: Chapter

References (19)

1. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-421.
2. European Medicines Agency CHMP assessment report for Xarelto. www.emea.europa.eu/humandocs/PDFs/EPAR/xarelto/H-944-en6.pdf
3. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880.
4. Halabi A, Maatouk H, Klause N et al. Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939)-an oral, direct, Factor Xa inhibitor. ASH Annual Meeting Abstracts 2006;108:913.
5. Tinel H, Huetter J, Perzborn E. Partial reversal of the anticoagulant effect of high-dose rivaroxaban-an oral, direct Factor Xa inhibitor-by recombinant factor VIIa in rats. Blood 2006;108:915.
6. Eriksson BL, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-2775.
7. Kakkar AK, Bredder B, Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-39.
8. Lassen MR, Ageno W, Borris LC, et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-2786.
9. Turpie A, Bauer K, Davidson B, et al. Comparison of rivaroxaban-an oral, direct factor Xa inhibitor-and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase 3 study). European Federation of National Associations of Orthopaedics and Traumatology Annual Meeting, May 29-June 1 2008, Nice, France. Abstract F85.
10. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116:180-187.
11. Stangier KJ, Rathgen K, Staehle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64: 292-303.
12. European Medicines Agency. CHMP Assessment Report For Pradaxa. www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf
13. Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006;62(5):527-537.
14. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-111.
15. Eriksson BI, Dahl OE, Rosencher N, et al. RE-MODEL Study Group. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5(11):2178-2185.
16. Eriksson BI, Dahl OE, Rosencher N, et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370(9591):949-956.
17. RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1):1-9.
18. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362(9397):1691-1698.
19. Albers GW, Diener HC, Frison L, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293(6):690-698.